Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773303 | 0.91 | BRD4 (0.47) | BRD4CREBBPBRD2 | |
| SCHEMBL17764916 | 0.91 | BRD4 (0.44) | BRD4CREBBPBRD2 | |
| SCHEMBL16110885 | 0.90 | BRD4 (0.61) | BRD4CREBBPBRD2 | |
| SCHEMBL16132458 | 0.90 | BRD4 (0.42) | BRD4CREBBPBRD2 | |
| SCHEMBL17764912 | 0.90 | BRD4 (0.42) | BRD4CREBBPBRD2 | |
| SCHEMBL17764913 | 0.89 | BRD4 (0.43) | BRD4CREBBPBRD2 | |
| SCHEMBL18635794 | 0.88 | BRD4 (0.44) | BRD4CREBBPBRD2ERN1 | |
| SCHEMBL17764927 | 0.87 | BRD4 (0.42) | BRD4CREBBPBRD2 | |
| SCHEMBL17764914 | 0.87 | BRD4 (0.48) | BRD4BRD2 | |
| SCHEMBL17764895 | 0.86 | BRD4 (0.44) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170182029-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-06-29 | — | — | US | claimed |
| US-9636328-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-02 | — | — | US | claimed |
| WO-2023274418-A1 | PROTEOLYSIS-TARGETING CHIMERIC COMPOUND | 南京明德新药研发有限公司 | 2023-01-05 | — | — | WO | disclosed |
| US-11026926-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| US-11026926-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| US-20190216782-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2019-07-18 | — | — | US | disclosed |
| US-20190216782-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2019-07-18 | — | — | US | disclosed |
| US-10226451-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-03-12 | — | — | US | disclosed |
| US-10226451-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-03-12 | — | — | US | disclosed |
| EP-3010917-B1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2018-01-31 | — | — | EP | disclosed |
| US-20170182029-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-06-29 | — | — | US | disclosed |
| US-9255089-B2 | Benzimidazolone derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255089-B2 | Benzimidazolone derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014160873-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026926-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 23/4885BRD2 3/4885 |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885CREBBP 23/4885BRD2 4/4885 |
| US-20170182029-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 21/4885BRD2 3/4885 |
| US-10226451-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 23/4885BRD2 3/4885 |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885CREBBP 23/4885BRD2 4/4885 |
| US-20190216782-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 21/4885BRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.